Login to Your Account

Calling in the Reserves

MS Drug's Therapeutic, Adverse Effects Separated in New Study

By Anette Breindl

Wednesday, May 11, 2011
Gilenya (fingolimod, Novartis AG) which the FDA approved in 2010, has shaped the market, as the first oral drug for multiple sclerosis. (See BioWorld Today, Sept. 23, 2010.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription